company background image
GILD

Gilead Sciences WBAG:GILD Stock Report

Last Price

€76.44

Market Cap

€96.8b

7D

-3.7%

1Y

26.5%

Updated

20 Jan, 2023

Data

Company Financials +

GILD Stock Overview

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally.

GILD fundamental analysis
Snowflake Score
Valuation2/6
Future Growth3/6
Past Performance0/6
Financial Health3/6
Dividends2/6

My Notes

New

Notes are coming soon

Gilead Sciences, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Gilead Sciences
Historical stock prices
Current Share PriceUS$76.44
52 Week HighUS$84.44
52 Week LowUS$52.24
Beta0.43
1 Month Change-5.38%
3 Month Change11.43%
1 Year Change26.51%
3 Year Change33.15%
5 Year Change12.74%
Change since IPO33.54%

Recent News & Updates

Recent updates

Shareholder Returns

GILDAT BiotechsAT Market
7D-3.7%-0.4%0.3%
1Y26.5%-3.4%-16.5%

Return vs Industry: GILD exceeded the Austrian Biotechs industry which returned -3.4% over the past year.

Return vs Market: GILD exceeded the Austrian Market which returned -16.5% over the past year.

Price Volatility

Is GILD's price volatile compared to industry and market?
GILD volatility
GILD Average Weekly Movement4.4%
Biotechs Industry Average Movement7.8%
Market Average Movement4.3%
10% most volatile stocks in AT Market7.7%
10% least volatile stocks in AT Market2.6%

Stable Share Price: GILD is not significantly more volatile than the rest of Austrian stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: GILD's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
198714,400Dan O'Dayhttps://www.gilead.com

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.

Gilead Sciences, Inc. Fundamentals Summary

How do Gilead Sciences's earnings and revenue compare to its market cap?
GILD fundamental statistics
Market Cap€96.83b
Earnings (TTM)€3.08b
Revenue (TTM)€25.05b

31.2x

P/E Ratio

3.8x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
GILD income statement (TTM)
RevenueUS$27.14b
Cost of RevenueUS$5.64b
Gross ProfitUS$21.50b
Other ExpensesUS$18.16b
EarningsUS$3.33b

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 02, 2023

Earnings per share (EPS)2.66
Gross Margin79.22%
Net Profit Margin12.29%
Debt/Equity Ratio119.8%

How did GILD perform over the long term?

See historical performance and comparison

Dividends

3.5%

Current Dividend Yield

109%

Payout Ratio